Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU
A new clinical trial is investigating Nu-3, an antimicrobial topical gel, for treating mildly infected diabetic foot ulcers (iDFUs). The gel aims to reduce bacteria in the wound and cure the infection, potentially speeding up healing and preventing serious complications. This Phase 2a study is testing three different doses of Nu-3 to determine which is most effective and safe. The trial is currently recruiting participants at multiple sites in the United States, including Los Angeles and Miami. Infected foot ulcers are a leading cause of hospitalizations and amputations in people with diabetes, so new treatments are urgently needed. While this trial is not available in China, its results may eventually lead to a new treatment option that could benefit patients worldwide, including those in China, where the burden of diabetic foot complications is rising. The study will monitor participants closely to assess the gel's safety and efficacy over a short period of use.
Key takeaways
- Nu-3 is an antimicrobial gel being tested in three different doses for mildly infected diabetic foot ulcers.
- The trial aims to see if the gel can reduce bacteria and cure the infection after 1-2 weeks of use.
- This is a Phase 2a study, an early but important step in determining the treatment's safety and effectiveness in humans.
- The trial is currently recruiting in the United States only, with no sites in China, so participation would require travel.
- Infected foot ulcers are a major cause of hospital stays and amputations in people with diabetes, highlighting the need for new treatments.
- Patients should discuss with their doctor the potential risks and benefits of newer topical treatments compared to standard care.
Read the full paper / source →
This content summarizes published medical research for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making treatment decisions.
Free consultation
Could this treatment help you?
Our DFU specialists review every inquiry personally. Tell us about your situation — response within 48 hours, no commitment required.
This website provides medical-information science popularization only. It does NOT provide online diagnosis, prescriptions, or medical advice. Consult a licensed physician for any medical decision.
Editor's note
This trial represents a promising step toward a new topical therapy that could directly combat infection at the wound site, potentially helping ulcers heal faster and reducing the risk of amputation. For patients in China, this treatment is not yet available, but its development underscores the global effort to address diabetic foot complications. If you are considering participating in a clinical trial abroad, be aware of the strict eligibility criteria and the need for close follow-up. Always consult your doctor before exploring experimental treatments, and remember that standard care remains effective for many patients. Ask your doctor about the latest advances in topical antimicrobials and whether any similar trials are planned in China.